Public Profile

Exelixis, Inc.

Exelixis, Inc., a prominent biotechnology firm headquartered in the United States, has established itself as a leader in the oncology sector since its founding in 1994. With a focus on developing innovative cancer therapies, Exelixis operates primarily in North America and has made significant strides in advancing targeted treatments for various malignancies. The company’s flagship product, cabozantinib, exemplifies its commitment to precision medicine, offering unique mechanisms of action that address complex tumour biology. Exelixis has achieved notable milestones, including successful clinical trials and strategic partnerships, solidifying its position in the competitive biopharmaceutical landscape. With a robust pipeline and a dedication to improving patient outcomes, Exelixis continues to be a key player in the fight against cancer.

DitchCarbon Score

How does Exelixis, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

20

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

Exelixis, Inc.'s score of 20 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.

76%

Let us know if this data was useful to you

Exelixis, Inc.'s reported carbon emissions

Exelixis, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives related to climate commitments. Without specific emissions figures or defined goals, it is challenging to assess their environmental impact or progress in reducing carbon emissions. The absence of data may indicate a need for further transparency in their sustainability efforts. As the industry increasingly prioritises climate action, it will be essential for Exelixis to establish and communicate clear commitments to reduce their carbon footprint in the future.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Exelixis, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Exelixis, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Exelixis, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Novimmune SA

CH
Research and development services (73)
Updated 2 days ago

Shattuck Labs, Inc.

US
Health and social work services (85)
Updated 2 days ago

Ionis Pharmaceuticals

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 2 days ago

Seagen Inc.

US
Health and social work services (85)
Updated 3 days ago
DitchCarbon Score

OSE Immunotherapeutics SA

FR
Health and social work services (85)
Updated 2 days ago

Bio-Thera Solutions, Ltd.

CN
Health and social work services (85)
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers